| Name | Title | Contact Details |
|---|
It for Health is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The all-in-one digital solution for gut health and disease. We`re helping people feel better, while lowering their cost of care. At Vivante, we`re taking on digestive disease because an astonishing 70 million people in the US are affected—that`s twice the number with diabetes and more than many other chronic conditions combined. Unlike other chronic conditions, though, digestive diseases are often untreated or misdiagnosed...because of stigma. Over half of adults with digestive trouble admit they haven`t even consulted a provider about their symptoms. This is unfortunate because chronic digestive symptoms take a toll on home life, work performance, romance, and even simple social events. And digestive disease is expensive! For most companies, GI claims are the #2 healthcare expense, second only to cancer. Specialty drugs for inflammatory bowel disease can run $70k per year for just ONE employee. Now is the time for employers and health plans to address digestive health, while at the same time providing REAL help to the millions who are struggling and don`t know where to turn. Our all-in-one digital program, GIThrive®, empowers people—through brilliant technology and advanced science—to spend less time worrying about their digestive symptoms and more time living life. A wonderful byproduct of the GIThrive success is reduced medical and Rx drug spending for employers, health plans and individuals.
The Cardiovascular Research Foundation (CRF) in New York City is an independent, non-profit academic institution dedicated to improving the survival and quality of life of patients with cardiovascular disease through research and education.
Longevity secrets from the worlds longest-lived people.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.